Macrophages in cholangiopathies
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Purpose of review: Cholangiopathies are a heterogeneous class of liver diseases where cholangiocytes are the main targets of liver injury. Although available and emerging therapies mainly target bile acids (ursodeoxycholic acid/UDCA, 24-Norursodeoxycholic acid/norUDCA) and related signaling pathways (obeticholic acid, fibrates, FXR, and PPAR agonists), the mechanisms underlying inflammation, ductular reaction and fibrosis in cholestatic liver diseases remain poorly understood. Recent findings: Data from patients with cholestatic diseases, such as primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC) as well as mouse models of biliary injury emphasize the role of immune cells in the pathogenesis of cholestatic disorders and indicate diverse functions of hepatic macrophages. Their versatile polarization phenotypes and their capacity to interact with other cell types (e.g. cholangiocytes, other immune cells) make macrophages central actors in the progression of cholangiopathies. Summary: In this review, we summarize recent findings on the response of hepatic macrophages to cholestasis and biliary injury and their involvement in the progression of cholangiopathies. Furthermore, we discuss how recent discoveries may foster the development of innovative therapies to treat patients suffering from cholestatic liver diseases, in particular, treatments targeting macrophages to limit hepatic inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537
Banales, J. M., Huebert, R. C., Karlsen, T., Strazzabosco, M., LaRusso, N. F., & Gores, G. J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0125-y · Cited by 517 · cited 1×
“angiopathies are associated with an accumulation of toxic bile acids causing liver injury and inflammation [1].”
BackgroundExpression and function of the bile acid receptor TGR5 in Kupffer cells
Keitel, V., Donner, M., Winandy, S., Kubitz, R., & Häussinger, D. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.171 · Cited by 418
Cholangiocyte organoids can repair bile ducts after transplantation in the human liver
Sampaziotis, F., Muraro, D., Tysoe, O. C., Sawiak, S., Beach, T. E., Godfrey, E. M., Upponi, S. S., Brevini, T., Wesley, B. T., Garcia-Bernardo, J., et al. (2021) · Science · doi:10.1126/science.aaz6964 · Cited by 394
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
Fickert, P., Hirschfield, G. M., Denk, G., Marschall, H.-U., Altorjay, I., Färkkilä, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.009 · Cited by 297
de Vries, E., Bolier, R., Goet, J., Parés, A., Verbeek, J., de Vree, M., Drenth, J., van Erpecum, K., van Nieuwkerk, K., van der Heide, F., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.10.001 · Cited by 224
Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice
Guicciardi, M. E., Trussoni, C. E., Krishnan, A., Bronk, S. F., Lorenzo Pisarello, M. J., O'Hara, S. P., Splinter, P. L., Gao, Y., Vig, P., Revzin, A., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.018 · Cited by 183
Reich, M., Spomer, L., Klindt, C., Fuchs, K., Stindt, J., Deutschmann, K., Höhne, J., Liaskou, E., Hov, J. R., Karlsen, T. H., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.03.029 · Cited by 121
Obeticholic acid-a new therapy in PBC and NASH
Chapman, R. W., & Lynch, K. D. (2020) · British Medical Bulletin · doi:10.1093/bmb/ldaa006 · Cited by 116
Kunzmann, L. K., Schoknecht, T., Poch, T., Henze, L., Stein, S., Kriz, M., Grewe, I., Preti, M., Hartl, J., Pannicke, N., et al. (2020) · Hepatology · doi:10.1002/hep.31140 · Cited by 93
Cited by
Cholangiokines: undervalued modulators in the hepatic microenvironment
Cai, X., Tacke, F., Guillot, A., & Liu, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192840 · Cited by 40
Self-citationA+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis
Chen, R., Huang, B., Lian, M., Wei, Y., Miao, Q., Liang, J., Ou, Y., Liang, X., Zhang, H., Li, Y., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.016 · Cited by 39
Liu, H., Yin, G., Franco Leonardi, B., Lan, T., Ait Ahmed, Y., Berger, H., Kohlhepp, M. S., Amiridze, N., Martagón Calderón, N., Frau, C., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334425 · Cited by 23
“Moreover, gene expression of Mrc1 was upregulated while gene expression of Cd36 , Nos2 and Il1b were down-regulated in mLMFs cultured with CM from Od- mBEC-si Orm2 (vs Od- mBEC-Ctrl) (online supplemental figure S12B).”
Self-citationKrishnan, A., Ozturk, N. B., Cutshaw, K. A., Guicciardi, M. E., Kitagataya, T., Olson, K. E., Pavelko, K. D., Sherman, W., Wixom, A. Q., Jalan-Sakrikar, N., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-52710-3 · Cited by 8
“This observation is consistent with prior studies conducted by us and others, reporting an increase in monocyte-derived macrophages in cholestatic disorders 7,19,21 .”
ResultMa, D., Liu, X., Li, J., Wu, H., Ma, J., & Tai, W. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.05.012 · Cited by 7
Metadata
- Authors
- Bruneau, A., Guillot, A., & Tacke, F.
- Venue
- Current Opinion in Gastroenterology
- Published
- 2021-12-22
- Volume
- 38
- Issue
- 2
- Pages
- 114-120
- ISSN
- 0267-1379 (ISSN-L)
- 1531-7056
- OpenAlex
- W4200283171
- Cited by
- 18
- References
- 16
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Macrophages in cholangiopathies. https://app.cochat.ai/papers/10.1097/mog.0000000000000814
- The paper
- Bruneau, A., Guillot, A., & Tacke, F. (2022). Macrophages in cholangiopathies. Current Opinion in Gastroenterology. https://doi.org/10.1097/mog.0000000000000814
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.